

VIRGINIA ACTS OF ASSEMBLY — CHAPTER

An Act to amend and reenact §§ 32.1-45.4 and 54.1-3466 of the Code of Virginia, and to repeal the third enactment of Chapter 183 of the Acts of Assembly of 2017, relating to comprehensive harm reduction programs.

[H 791]

Approved

Be it enacted by the General Assembly of Virginia:

1. That §§ 32.1-45.4 and 54.1-3466 of the Code of Virginia are amended and reenacted as follows:

§ 32.1-45.4. (Expires July 1, 2020) Comprehensive harm reduction programs.

A. The Commissioner or his designee may authorize, the director of a local department of health, or any other organization that promotes scientifically proven methods of mitigating health risks associated with drug use and other high-risk behaviors may to establish and operate local or regional comprehensive harm reduction programs during a declared public health emergency that include the provision of sterile hypodermic needles and syringes and disposal of used hypodermic needles and syringes. The objectives of such programs shall be to (i) reduce the spread of HIV, viral hepatitis, and other blood-borne diseases in Virginia the Commonwealth; (ii) reduce the transmission of blood-borne diseases through needlestick injuries to law-enforcement and other emergency personnel; and (iii) provide information to individuals who inject drugs regarding addiction recovery treatment services and encourage such individuals to participate in evidence-based substance use treatment programs; (iv) prevent opioid overdose deaths through distribution of naloxone or other opioid antagonists; and (v) incentivize the safe return and disposal of hypodermic needles and syringes. Such programs shall be located in communities where data indicate, in accordance with criteria established pursuant to subsection B, a risk of transmission of, or increases in the transmission of, HIV, viral hepatitis, or other blood-borne disease as a result of injection drug use. Such Comprehensive harm reduction programs established by the Commissioner pursuant to this section shall be operated by local health departments or affiliated organizations with which the Department contracts.

B. The Department shall establish criteria to determine the level of risk and the level of readiness for comprehensive harm reduction of a community. Such criteria shall address the extent to which unsafe injection of drugs is occurring, socioeconomic factors, and readiness for comprehensive harm reduction and shall utilize data that address, at a minimum, (i) HIV and hepatitis disease morbidity, (ii) drug overdose deaths, (iii) poverty level, (iv) unemployment rate, (v) prescription opioid volume, (vi) potential to provide medication-assisted treatment, (vii) prevalence of treatment for drug overdose, (viii) emergency medical services utilization for drug overdose, (ix) administration of naloxone, (x) substance-use disorder admissions to behavioral health facilities, (xi) arrests for drug possession or sales or other drug related crime, (xii) the support of the local governing body, (xiii) the support of law enforcement, (xiv) the existence of a local entity with programmatic administrative capacity, and (xv) access to health care and behavioral health care services.

C. Comprehensive A comprehensive harm reduction programs program established pursuant to this section shall be administered pursuant to standards and protocols established by the Commissioner after the declaration of a public health emergency and approved by the Secretary of Health and Human Resources and the Secretary of Public Safety and Homeland Security. Such standards and protocols shall address include (i) the disposal of used hypodermic needles and syringes; (ii) the provision of hypodermic needles and syringes and other injection supplies at no cost and in quantities sufficient to ensure that needles, hypodermic syringes, and other injection supplies are not shared or reused; (iii) reasonable and adequate security of program sites, equipment, and personnel; (iv) the provision of educational materials concerning (a) substance use disorder prevention, (b) overdose prevention, (c) the prevention of transmission of HIV, viral hepatitis, and other blood-borne diseases, (d) available mental health treatment options, including referrals for mental health treatment, and (e) available substance use disorder treatment options, which shall include options for medication assisted treatment of substance use disorder, including referrals for treatment; (v) access to overdose prevention kits that contain naloxone or other opioid antagonist approved by the U.S. Food and Drug Administration for opioid overdose reversal; (vi) individual harm reduction counseling, including individual consultations regarding appropriate mental health or substance use disorder treatment; and (vii) verification that a hypodermic needle or syringe or other injection supplies were obtained from a comprehensive harm reduction program established pursuant to this section.

C. The director of a local health department or representative of any other organization authorized

ENROLLED

HB791ER

57 to establish a comprehensive harm reduction program pursuant to this section shall notify the
 58 Department, in a manner and form specified by the Department, of his intent to establish a
 59 comprehensive harm reduction program. Such notice shall include (i) the name of the local health
 60 department or organization that will operate the comprehensive harm reduction program, (ii) a
 61 description of the geographic area and population to be served by the comprehensive harm reduction
 62 program, and (iii) a description of the methods by which the comprehensive harm reduction program
 63 will comply with the requirements of subsection B, including a written security plan that provides for the
 64 reasonable and adequate security of the comprehensive harm reduction program site, equipment, and
 65 personnel.

66 D. The Commissioner may authorize persons who are not otherwise authorized by law to dispense or
 67 distribute Written security plans required pursuant to clause (iii) of subsection C shall be filed annually
 68 with each local law-enforcement agency serving the jurisdiction in which the comprehensive harm
 69 reduction program is located for their consideration.

70 E. The provisions of §§ 18.2-250, 18.2-265.3, and 54.1-3466 shall not apply to a person who
 71 dispenses or distributes hypodermic needles and syringes to dispense or distribute hypodermic needles
 72 and syringes as part of a comprehensive harm reduction program during a declared public health
 73 emergency and in accordance with standards and protocols established pursuant to subsection C this
 74 section.

75 F. The provisions of §§ 18.2-250, 18.2-265.3, and 54.1-3466 relating to possession of a controlled
 76 substance, drug paraphernalia, and controlled paraphernalia shall not apply to such authorized persons
 77 who are acting in accordance with the standards and protocols of any person acting on behalf or for the
 78 benefit of a comprehensive harm reduction program for the duration of the declared public health
 79 emergency when such possession is incidental to the provision of services as part of a comprehensive
 80 harm reduction program established pursuant to this section.

81 G. The provisions of §§ 18.2-250, 18.2-265.3, and 54.1-3466 relating to possession of a controlled
 82 substance, drug paraphernalia, and controlled paraphernalia shall not apply to any person receiving
 83 services from a comprehensive harm reduction program established pursuant to this section, when (i)
 84 such controlled substance is a residual amount contained in a used needle, used hypodermic syringe, or
 85 used injection supplies obtained from or returned to a comprehensive harm reduction program
 86 established pursuant to this section, or (ii) such paraphernalia is obtained from a comprehensive harm
 87 reduction program established pursuant to this section, as evidenced by the verification required
 88 pursuant to clause (vii) of subsection B.

89 H. Every local health department or other organization operating a comprehensive harm reduction
 90 program pursuant to this section shall report annually by July 1 to the Department regarding, for the
 91 previous calendar year, (i) the number of individuals served by the comprehensive harm reduction
 92 program; (ii) the number of needles, hypodermic syringes, and other injection supplies distributed by the
 93 comprehensive harm reduction program; (iii) the number of overdose prevention kits described in clause
 94 (v) of subsection B distributed by the comprehensive harm reduction program; and (iv) the number and
 95 type of referrals to mental health or substance use disorder treatment services provided to individuals
 96 served by the comprehensive harm reduction program, including the number of individuals referred to
 97 programs that provide naloxone or other opioid antagonists approved by the U.S. Food and Drug
 98 Administration for opioid overdose reversal.

99 I. Except in the case of a comprehensive harm reduction program established by the Commissioner,
 100 no state funds shall be used to purchase needles or hypodermic syringes distributed by a comprehensive
 101 harm reduction program established pursuant to this section.

102 **§ 54.1-3466. Possession or distribution of controlled paraphernalia; definition of controlled**
 103 **paraphernalia; evidence; exceptions.**

104 A. For purposes of this chapter, "controlled paraphernalia" means (i) a hypodermic syringe, needle,
 105 or other instrument or implement or combination thereof adapted for the administration of controlled
 106 dangerous substances by hypodermic injections under circumstances that reasonably indicate an intention
 107 to use such controlled paraphernalia for purposes of illegally administering any controlled drug or (ii)
 108 gelatin capsules, glassine envelopes, or any other container suitable for the packaging of individual
 109 quantities of controlled drugs in sufficient quantity to and under circumstances that reasonably indicate
 110 an intention to use any such item for the illegal manufacture, distribution, or dispensing of any such
 111 controlled drug. Evidence of such circumstances shall include, but not be limited to, close proximity of
 112 any such controlled paraphernalia to any adulterants or equipment commonly used in the illegal
 113 manufacture and distribution of controlled drugs including, but not limited to, scales, sieves, strainers,
 114 measuring spoons, staples and staplers, or procaine hydrochloride, mannitol, lactose, quinine, or any
 115 controlled drug, or any machine, equipment, instrument, implement, device, or combination thereof that
 116 is adapted for the production of controlled drugs under circumstances that reasonably indicate an
 117 intention to use such item or combination thereof to produce, sell, or dispense any controlled drug in

violation of the provisions of this chapter. "Controlled paraphernalia" does not include narcotic testing products used to determine whether a controlled substance contains fentanyl or a fentanyl analog.

B. Except as authorized in this chapter, it is unlawful for any person to possess controlled paraphernalia.

C. Except as authorized in this chapter, it is unlawful for any person to distribute controlled paraphernalia.

D. A violation of this section is a Class 1 misdemeanor.

E. The provisions of this section shall not apply to persons who have acquired possession and control of controlled paraphernalia in accordance with the provisions of this article or to any person who owns or is engaged in breeding or raising livestock, poultry, or other animals to which hypodermic injections are customarily given in the interest of health, safety, or good husbandry; or to hospitals, physicians, pharmacists, dentists, podiatrists, veterinarians, funeral directors and embalmers, persons to whom a permit has been issued, manufacturers, wholesalers, or their authorized agents or employees when in the usual course of their business, if the controlled paraphernalia lawfully obtained continue to be used for the legitimate purposes for which they were obtained.

F. The provisions of this section and of § 18.2-265.3 shall not apply to (i) a person who dispenses naloxone in accordance with the provisions of subsection Y of § 54.1-3408 and who, in conjunction with such dispensing of naloxone, dispenses or distributes hypodermic needles and syringes for injecting such naloxone or (ii) a person who possesses naloxone that has been dispensed in accordance with the provisions of subsection Y of § 54.1-3408 and possesses hypodermic needles and syringes for injecting such naloxone in conjunction with such possession of naloxone.

G. The provisions of this section and of § 18.2-265.3 shall not apply to (i) a person who possesses or distributes controlled paraphernalia on behalf of or for the benefit of a comprehensive harm reduction program established pursuant to § 32.1-45.4 or (ii) a person who possesses controlled paraphernalia obtained from a comprehensive harm reduction program established pursuant to § 32.1-45.4.

2. That the third enactment of Chapter 183 of the Acts of Assembly of 2017 is repealed.